# Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension

> **NCT00686803** · PHASE2 · COMPLETED · sponsor: **Palatin Technologies, Inc** · enrollment: 21 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** PL3994
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00686803
- **Lead sponsor:** Palatin Technologies, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2013-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00686803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00686803, "Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00686803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*